GO:0061629 RNA polymerase II-specific DNA-binding transcription factor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061629 describes the molecular function of binding to a sequence-specific DNA-binding RNA polymerase II transcription factor, a key step in modulating transcription.
• This binding event is essential for both basal and activated RNA polymerase II transcription, as shown by studies on TFIIA and PC4/Sub1 [3, 4, 8].
• The function is distinct from RNA polymerase III-specific factor binding, although some factors like TFIIIC contain domains resembling Pol II factors [1, 5].
• Key proteins involved include TFIIA, TFIIB-related factors, and coactivators such as PC4/Sub1, which interact with sequence-specific activators or repressors [3, 4, 8].
• Dysregulation of these interactions can contribute to diseases such as renal fibrosis and cancer, as suggested by studies on NFκB signaling and HIC1 [2, 6].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of these binding events in disease contexts [2, 6].
Description
The Gene Ontology term GO:0061629, RNA polymerase II-specific DNA-binding transcription factor binding, defines a molecular function where a protein interacts selectively and non-covalently with a sequence-specific DNA-binding RNA polymerase II transcription factor to modulate transcription. This function is central to the regulation of gene expression because it bridges sequence-specific DNA-binding factors with the general transcriptional machinery or co-regulators, thereby influencing the rate of messenger RNA synthesis [3, 4]. Researchers study this term to understand how transcription is activated or repressed in response to developmental and environmental signals, and how disruptions contribute to disease [2, 6]. Experimental evidence from yeast and human systems has identified factors such as TFIIA and PC4/Sub1 as key players in this binding function [3, 4, 8]. For example, the testis-specific TFIIA tau stimulates TATA-binding protein-DNA binding and transcription activation, illustrating a direct role in Pol II transcription. Similarly, the coactivator PC4/Sub1 has multiple functions in RNA polymerase II transcription, including interactions with sequence-specific factors. These findings underscore the importance of GO:0061629 in both basal and regulated transcription.
RNA polymerase II-specific DNA-binding transcription factor binding At A Glance
| GO ID | GO:0061629 |
|---|---|
| GO term | RNA polymerase II-specific DNA-binding transcription factor binding |
| Ontology | molecular_function |
| Synonym | RNA polymerase II activating transcription factor binding; RNA polymerase II repressing transcription factor binding; RNA polymerase II sequence-specific DNA binding transcription factor binding; RNA polymerase II sequence-specific DNA-binding transcription factor binding; RNA polymerase II transcription factor binding |
| Major function | Binding to sequence-specific DNA-binding RNA polymerase II transcription factors to modulate transcription |
| Definition source | QuickGO |
| Related processes | Transcription regulation, signal transduction, development |
| Example proteins | TFIIA, PC4/Sub1, TFIIB-related factors |
What Is GO:0061629?
GO:0061629 is a molecular function term describing the binding to a sequence-specific DNA-binding RNA polymerase II transcription factor. Such transcription factors interact selectively and non-covalently with specific DNA sequences to modulate transcription. The binding event itself is non-covalent and occurs between a protein and a transcription factor that is specific to RNA polymerase II transcription. This function is distinct from binding to general transcription factors or to RNA polymerase III-specific factors, although some structural similarities exist [1, 5].
Why Is RNA polymerase II-specific DNA-binding transcription factor binding Important in Cell Biology?
GO:0061629 is critical because it represents a fundamental mechanism by which sequence-specific transcription factors communicate with the RNA polymerase II machinery to control gene expression programs. This binding function is required for both basal and activated transcription, as demonstrated by studies showing that TFIIA and PC4/Sub1 directly stimulate transcription activation [3, 4, 8]. Dysregulation of these interactions can lead to diseases such as renal fibrosis and cancer, where aberrant transcription factor binding drives pathological gene expression [2, 6]. Therefore, understanding this term helps researchers identify therapeutic targets and design experiments to modulate transcription in disease models.
• Essential for basal and activated RNA polymerase II transcription [3, 8].
• Mediates signal-dependent gene expression changes in response to external cues.
• Involved in developmental processes through testis-specific TFIIA tau.
• Contributes to disease mechanisms such as renal fibrosis via NFκB signaling.
• Potential role in cancer through transcription factor HIC1 and its SNPs.
• Target for therapeutic intervention in transcription-driven diseases [2, 6].
• Provides a basis for understanding coactivator function like PC4/Sub1.
• Distinct from RNA polymerase III-specific factor binding, highlighting specificity [1, 5].
• Enables experimental dissection using CRISPR models [2, 6].
• Supports bioinformatics analysis of transcription factor networks.
Molecular Mechanism of RNA polymerase II-specific DNA-binding transcription factor binding
Recognition and Binding to Sequence-Specific Transcription Factors
In simple terms: This step is about how a protein grabs onto a transcription factor that reads specific DNA sequences.
The binding function described by GO:0061629 involves non-covalent interaction with a sequence-specific DNA-binding RNA polymerase II transcription factor. Such transcription factors selectively recognize DNA sequences to modulate transcription. For example, the coactivator PC4/Sub1 interacts with sequence-specific activators to regulate RNA polymerase II transcription. This binding is often mediated by protein-protein interaction domains that recognize the transcription factor's activation or repression domains. The specificity ensures that only appropriate transcription factors are engaged, thereby linking DNA-binding events to transcriptional outcomes [3, 4].
Stimulation of TATA-Binding Protein-DNA Binding
In simple terms: After binding, the protein can help the TATA-binding protein attach to DNA, which is a key step to start transcription.
The testis-specific transcription factor IIA (TFIIA tau) stimulates TATA-binding protein-DNA binding and transcription activation, demonstrating a direct role in facilitating the assembly of the preinitiation complex. This stimulation is a consequence of binding to sequence-specific factors or general factors, and it enhances the efficiency of transcription initiation. Similarly, yeast TFIIA has a polymerase II-specific role in basal and activated transcription, indicating that this binding function is conserved and essential.
Coactivator Function and Multiple Roles in Transcription
In simple terms: Some proteins that perform this binding have more than one job, like helping both activate and repress transcription.
PC4/Sub1 is a transcriptional coactivator with multiple functions in RNA polymerase II transcription, including binding to sequence-specific transcription factors and influencing both activation and repression. This multifunctionality suggests that GO:0061629 encompasses interactions that can either enhance or inhibit transcription depending on context. The binding to RNA polymerase II-specific DNA-binding transcription factors is a central aspect of its coactivator role, and it may also interact with general transcription factors to modulate the preinitiation complex.
Specificity and Distinction from RNA Polymerase III Factors
In simple terms: This binding is specific to RNA polymerase II transcription factors, not those for RNA polymerase III, even though some factors look similar.
The term GO:0061629 is specific to RNA polymerase II-specific DNA-binding transcription factors. However, structural studies have revealed that RNA polymerase III-specific general transcription factor IIIC contains a heterodimer resembling TFIIF Rap30/Rap74, indicating evolutionary relationships but distinct functions. Similarly, a yeast TFIIB-related factor is involved in RNA polymerase III transcription, highlighting that while some factors share homology, their binding specificities differ. This distinction is crucial for accurate annotation and experimental design.
Key Genes Involved in GO:0061629 RNA polymerase II-specific DNA-binding transcription factor binding
The following genes and proteins are directly implicated in RNA polymerase II-specific DNA-binding transcription factor binding, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TFIIA | Stimulates TATA-binding protein-DNA binding and transcription activation | Testis-specific isoform TFIIA tau studied for developmental roles |
| PC4/Sub1 | Transcriptional coactivator with multiple functions in RNA polymerase II transcription | Model for coactivator binding to sequence-specific factors |
| TFIIB | General transcription factor; related factors exist in RNA polymerase III | Yeast TFIIB-related factor involved in Pol III transcription |
| TFIIIC | RNA polymerase III-specific general transcription factor | Contains heterodimer resembling TFIIF Rap30/Rap74 |
| HIC1 | Sequence-specific transcriptional repressor | SNPs analyzed computationally for disease associations |
| NFκB | Sequence-specific transcription factor involved in immune and inflammatory responses | Modulated by Siling decoction in renal fibrosis via AKT/IKKβ/NFκB pathway |
| U6 promoter factors | RNA polymerase III and II transcription initiation factors | Both Pol III and Pol II initiate from human U6 promoter in vitro |
| TFIIAtau | Testis-specific TFIIA variant | Stimulates TBP-DNA binding and transcription activation |
| Sub1 | Yeast homolog of PC4 | Multiple functions in RNA polymerase II transcription |
| Rap30 | TFIIF subunit | Homologous domain in TFIIIC heterodimer |
| Rap74 | TFIIF subunit | Homologous domain in TFIIIC heterodimer |
| TFIIB-related factor | Involved in RNA polymerase III transcription | Yeast factor with similarity to TFIIB |
| TATA-binding protein | General transcription factor | Stimulated by TFIIA tau |
| AKT | Kinase in signaling pathway | Part of AKT/IKKβ/NFκB pathway in renal fibrosis |
| IKKβ | Kinase in NFκB pathway | Modulated by Siling decoction |
| NFκB | Transcription factor | Target of AKT/IKKβ signaling |
| HIC1 | Transcription factor | Computational SNP analysis |
How Is RNA polymerase II-specific DNA-binding transcription factor binding Regulated?
The binding function described by GO:0061629 is regulated at multiple levels. Post-translational modifications of either the binding protein or the transcription factor can alter affinity and specificity. For example, the coactivator PC4/Sub1 is subject to phosphorylation that modulates its interactions. Signaling pathways such as AKT/IKKβ/NFκB can influence the availability or activity of sequence-specific transcription factors, thereby affecting binding events. Additionally, the expression levels of the binding proteins themselves are regulated during development and in response to stress, as seen with testis-specific TFIIA tau. These regulatory mechanisms ensure that transcription is tightly controlled.
RNA polymerase II-specific DNA-binding transcription factor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NFκB | Renal fibrosis | Rat model of adenine-induced renal fibrosis treated with Siling decoction |
| HIC1 | Cancer (computational prediction) | Cell lines with HIC1 SNPs for functional assays |
| TFIIA tau | Male infertility / spermatogenesis defects | Testis-specific knockout mouse models |
| PC4/Sub1 | Transcription-related diseases | Yeast and human cell lines with Sub1/PC4 mutations |
| TFIIB-related factor | RNA polymerase III-related disorders | Yeast models with factor deletions |
Renal Fibrosis and NFκB Signaling
Siling decoction ameliorates adenine-induced renal fibrosis in rats by modulating the AKT/IKKβ/NFκB signaling pathway. NFκB is a sequence-specific DNA-binding transcription factor, and its binding to coactivators or general factors is a key step in the transcription of pro-fibrotic genes. This study suggests that targeting the binding function GO:0061629 could be therapeutic in renal fibrosis.
Cancer and Transcription Factor Dysregulation
Computational analysis of single nucleotide polymorphisms in the human HIC1 gene, a sequence-specific transcriptional repressor, identified variants that may affect its function. HIC1 binds to DNA and interacts with cofactors; disruptions in these interactions could contribute to cancer. Thus, GO:0061629 is relevant to understanding how mutations in transcription factors or their binding partners drive oncogenesis.
Developmental Disorders and Testis-Specific Transcription
The testis-specific transcription factor IIA (TFIIA tau) stimulates TATA-binding protein-DNA binding and transcription activation, playing a role in spermatogenesis. Defects in this binding function could lead to male infertility or developmental abnormalities. Studying GO:0061629 in this context may reveal mechanisms of tissue-specific gene regulation.
From RNA polymerase II-specific DNA-binding transcription factor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a candidate binding protein affect transcription? | CRISPR knockout in cell lines (e.g., HEK293T) |
| Does a point mutation in the transcription factor alter binding affinity? | CRISPR point mutation knock-in in disease-relevant cells |
| Can a tagged version of the binding protein be used for interaction studies? | CRISPR knock-in of epitope tag (e.g., FLAG, HA) |
| Does overexpression of the binding protein enhance transcription? | CRISPR overexpression via safe-harbor locus |
| Which genes are regulated by the binding event? | CRISPR library screening coupled with RNA-seq |
| Does the binding event contribute to renal fibrosis? | Rat model with CRISPR-mediated knockout of NFκB pathway components |
How to Study the RNA polymerase II-specific DNA-binding transcription factor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide binding sites of transcription factors | Mapping regulatory regions |
| Co-IP | Protein-protein interactions | Identifying binding partners |
| Reporter assay | Transcriptional activity | Functional validation of binding events |
| CRISPR knockout | Loss-of-function effects | Testing causality of candidate genes |
| CRISPR activation | Gain-of-function effects | Overexpression studies |
| RNA-seq | Global gene expression changes | Downstream consequences of binding |
| Proteomics | Protein complex composition | Identifying novel components |
| Bioinformatics | Prediction of binding motifs and networks | Computational analysis of SNPs |
Chromatin Immunoprecipitation (ChIP) and ChIP-seq
ChIP is used to detect physical interactions between a protein and DNA in vivo. When combined with sequencing (ChIP-seq), it can map genome-wide binding sites of sequence-specific transcription factors and their cofactors, providing insights into GO:0061629 function. This method is essential for identifying which genes are directly regulated by the binding event.
Co-immunoprecipitation (Co-IP) and Pull-down Assays
Co-IP and pull-down assays detect protein-protein interactions, such as the binding between a coactivator and a sequence-specific transcription factor. These methods can confirm the physical association underlying GO:0061629 and identify novel binding partners. They are often used in conjunction with mass spectrometry to identify components of the complex.
Reporter Assays and Transcriptional Activity
Reporter assays use a promoter containing binding sites for a specific transcription factor driving a luciferase or fluorescent reporter. By co-expressing the binding protein of interest, researchers can measure changes in transcriptional activity, thereby assessing the functional impact of GO:0061629. This method is quantitative and suitable for high-throughput screening.
CRISPR-based Genetic Screens
CRISPR knockout or activation screens can identify genes that modulate the binding function or its downstream effects. For example, a genome-wide CRISPR screen could reveal factors required for NFκB-mediated transcription in renal fibrosis models. Such screens are powerful for discovering novel regulators of GO:0061629.
How CRISPR Can Be Used to Study GO:0061629 RNA polymerase II-specific DNA-binding transcription factor binding
Knockout
CRISPR knockout is used to completely ablate the expression of a gene encoding a protein involved in GO:0061629, such as PC4/Sub1 or TFIIA. This allows researchers to assess the loss-of-function consequences on transcription and cellular phenotypes. For example, knocking out NFκB pathway components in rat models can reveal their role in renal fibrosis.
Point Mutation
CRISPR point mutation introduces specific nucleotide changes to mimic disease-associated variants or to disrupt key interaction domains. This is particularly useful for studying SNPs in transcription factors like HIC1, where a single amino acid change may alter binding affinity. Point mutations can be introduced via homology-directed repair with a donor template.
Knock-in
CRISPR knock-in can insert epitope tags (e.g., FLAG, HA) or fluorescent proteins into endogenous loci to enable detection and purification of the binding protein. This facilitates interaction studies and imaging of the protein in its native context. Knock-in of reporter genes can also be used to monitor transcriptional activity.
Overexpression
CRISPR overexpression, often achieved by inserting a strong promoter or using CRISPR activation (CRISPRa), allows researchers to increase the levels of a binding protein or transcription factor. This can enhance transcription of target genes and help identify gain-of-function phenotypes. Overexpression models are valuable for studying dosage effects in disease.
How EDITGENE Supports RNA polymerase II-specific DNA-binding transcription factor binding Research
Researchers studying RNA polymerase II-specific DNA-binding transcription factor binding-related genes often need to determine whether a candidate gene is causally involved in transcriptional regulation or disease. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic modifications, from knockout to knock-in, in a variety of cell models.
Contact EDITGENE today to design your custom CRISPR model for RNA polymerase II-specific DNA-binding transcription factor binding research.
Frequently Asked Questions About RNA polymerase II-specific DNA-binding transcription factor binding
What is GO:0061629?
GO:0061629 is a Gene Ontology molecular function term for RNA polymerase II-specific DNA-binding transcription factor binding, which describes the non-covalent interaction with sequence-specific DNA-binding RNA polymerase II transcription factors to modulate transcription.
What genes are involved in RNA polymerase II-specific DNA-binding transcription factor binding?
Key genes include TFIIA, PC4/Sub1, TFIIB, and NFκB, among others, as identified in studies on transcription regulation [3, 4, 2].
How is RNA polymerase II-specific DNA-binding transcription factor binding studied?
Common methods include ChIP-seq, co-immunoprecipitation, reporter assays, and CRISPR-based genetic screens [4, 3, 6].
Why is RNA polymerase II-specific DNA-binding transcription factor binding important?
It is essential for basal and activated transcription, and its dysregulation is linked to diseases such as renal fibrosis and cancer [2, 6].
What diseases are associated with defects in this binding function?
Renal fibrosis, cancer, and potentially male infertility due to testis-specific TFIIA tau defects [2, 6, 3].
Can CRISPR be used to study RNA polymerase II-specific DNA-binding transcription factor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of this binding function in disease contexts [2, 6].
What is the difference between RNA polymerase II and RNA polymerase III transcription factor binding?
RNA polymerase II-specific binding involves factors that regulate mRNA synthesis, while RNA polymerase III-specific factors regulate tRNA and other small RNAs; some structural similarities exist but functions are distinct [1, 5].
Which proteins are known to perform this binding function?
Proteins such as TFIIA, PC4/Sub1, and TFIIB-related factors have been shown to bind RNA polymerase II-specific transcription factors [3, 4, 5].
How does PC4/Sub1 function in RNA polymerase II transcription?
PC4/Sub1 is a coactivator with multiple functions, including binding to sequence-specific transcription factors and modulating both activation and repression.
What model systems are used to study this binding function?
Yeast, human cell lines, and rat models are commonly used, with techniques like CRISPR and biochemical assays [4, 2, 6].
Conclusion
GO:0061629, RNA polymerase II-specific DNA-binding transcription factor binding, is a fundamental molecular function that bridges sequence-specific transcription factors with the RNA polymerase II machinery. Through interactions mediated by proteins such as TFIIA and PC4/Sub1, this binding event controls gene expression programs essential for development and homeostasis [3, 4]. Dysregulation of these interactions contributes to diseases including renal fibrosis and cancer, making them attractive therapeutic targets [2, 6]. Continued research using CRISPR models and advanced genomics will further elucidate the mechanisms and disease relevance of this important function.
References
- 1. Taylor NM et al.. 2013. RNA polymerase III-specific general transcription factor IIIC contains a heterodimer resembling TFIIF Rap30/Rap74.. Nucleic Acids Res 41(19):9183-96 PMID: 23921640
- 2. Zeng L et al.. 2024. Siling decoction ameliorates adenine-induced renal fibrosis in rats by the AKT/IKKβ/NFκB signaling pathway.. Phytomedicine 135:156228 PMID: 39550923
- 3. Ozer J et al.. 2000. A testis-specific transcription factor IIA (TFIIAtau) stimulates TATA-binding protein-DNA binding and transcription activation.. J Biol Chem 275(1):122-8 PMID: 10617594
- 4. Calvo O et al.. 2005. The transcriptional coactivator PC4/Sub1 has multiple functions in RNA polymerase II transcription.. EMBO J 24(5):1009-20 PMID: 15692559
- 5. Colbert T et al.. 1992. A yeast TFIIB-related factor involved in RNA polymerase III transcription.. Genes Dev 6(10):1940-9 PMID: 1398071
- 6. Annanya A et al.. 2024. Computational Analysis of Single Nucleotide Polymorphisms in Human HIC1 Gene.. Cureus 16(3):e56664 PMID: 38646326
- 7. Park JS et al.. 1995. Both RNA polymerase III and RNA polymerase II accurately initiate transcription from a human U6 promoter in vitro.. Biochem Biophys Res Commun 214(3):934-40 PMID: 7575566
- 8. Kang JJ et al.. 1995. Analysis of the yeast transcription factor TFIIA: distinct functional regions and a polymerase II-specific role in basal and activated transcription.. Mol Cell Biol 15(3):1234-43 PMID: 7862117
